Physician profile
Robert S Rubenstein
NPI 1437185279
$98,589.32
in general payments reported to CMS, 2019-2025
70 companies · $3,276 in 2025
The $3,276 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $18K · 2021: $29K · 2022: $17K · 2023: $8,411 · 2024: $7,323 · 2025: $3,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,432 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,681 · Travel and Lodging: $327 · Education: $293 · Consulting Fee: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,432.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,681.25 |
| Travel and Lodging | $326.57 |
| Education | $293.37 |
| Consulting Fee | $277.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $45,565.55 | 2019-2021 | |
| Abbvie INC. | $37,048.51 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Genzyme Corporation | $1,150.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,002.27 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $999.28 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $836.40 | 2019-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $788.56 | 2019-2025 | Mavenclad |
| Lilly USA, LLC | $733.43 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Biogen, INC. | $699.19 | 2019-2025 | Tysabri, Vumerity |
| Pfizer INC. | $698.55 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $637.48 | 2019-2025 | Nuplazid, Daybue |
| Ucb, INC. | $516.40 | 2020-2025 | Rystiggo, Briviact, Nayzilam |
| Amgen INC. | $483.94 | 2019-2024 | Uplizna |
| Argenx US, INC. | $480.30 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $437.79 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rubenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.